News, analysis, and explainers connected to Regulation across the CryptoCompass archive.
Newest first
Key Insights: Franklin Templeton registers two new Bitcoin ETFs for Nasdaq trading. FBEQ and FIBT charge management fees of 0.09% and 0.19%. Nasdaq registration is a listing step, not SEC app
Prediction markets Kalshi and Polymarket together recorded their highest-ever weekly crypto trading volume. Kalshi and Polymarket together recorded $2.7 billion in weekly crypto trading volum
Initia’s blockchain has stopped. On October 23, 2026 at 15:41:30 UTC the project halted its layer 1 blockchain and the rollups built on top of it, after an attacker was able to create tokens
Switzerland’s financial regulator has approved the country’s first Bitcoin exchange-traded fund, a development that marks a new chapter for regulated crypto investment in one of Europe’s most
Ondo Finance is a platform that brings real financial assets onto the blockchain as tokens: short-dated US Treasuries, equities and ETFs. Anyone searching for Ondo is usually looking for two
Chainlink and LG CNS, the IT services arm of South Korea’s LG Group, announced a partnership on October 22, 2026 to build infrastructure for Korea’s institutional digital asset market The rel
Cardano’s latest recovery is under pressure, and analyst V believes ADA could face another painful test before a lasting bottom develops. His warning comes as the project advances network upg
What to Know Renaat Ver Eecke built an extensive career in technology management, overseeing international software businesses before joining Ripple Treasury’s executive leadership. Ver Eecke
Kingz Casino (KINGZ) Crypto Presale Overview: Tokenomics, Rewards, and Risks The Kingz Casino presale has become one of the more talked about gaming token sales on Ethereum this year. KINGZ i
What is documented: the seven US spot funds on Solana gave up a net $30.3 million over the five trading days to October 22, and on October 22 not one of them recorded an inflow. Our assessmen
TLDR Roche stock jumps 2.60% as Phase 3 kidney drug results boost market momentum. Sefaxersen cuts proteinuria by 43.1% in a pivotal Phase 3 IgA nephropathy trial. Phase 3 data show no new sa
TLDR CELC stock fell 0.49% to $65.25, then dipped another 1.39% after hours to $64.34. Gedatolisib triplet delivers 21.5 months without progression in one key subgroup. Triplet response rate
